OSE Immunotherapeutics S.A.
PAR: OSE.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc Le Bozec
- Employees
- 64
- Headquarters
- Nantes, France
- IPO year
- 2015
- Market cap
- €86.7M
- Website
- https://www.ose-immuno.com
Loading OSE…
Loading profile data…Frequently asked questions about OSE
What does OSE Immunotherapeutics S.A. (OSE.PA) do?
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian can...
Where does OSE.PA trade?
OSE Immunotherapeutics S.A. (OSE.PA) trades on the Euronext Paris.
What sector is OSE.PA in?
OSE Immunotherapeutics S.A. (OSE.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OSE Immunotherapeutics S.A.?
Marc Le Bozec is the chief executive officer of OSE Immunotherapeutics S.A. (OSE.PA).
Where is OSE Immunotherapeutics S.A. headquartered?
OSE Immunotherapeutics S.A. is headquartered in France.
Does OSE.PA pay a dividend?
OSE Immunotherapeutics S.A. (OSE.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OSE.PA go public?
OSE Immunotherapeutics S.A. (OSE.PA) completed its initial public offering in 2015.